Results 211 to 220 of about 35,993 (244)

Pharmacology: Inhibitors of P2Y12

2017
Dual antiplatelet treatment consisting of aspirin and a P2Y12 inhibitor represents the cornerstone of treatment in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention. P2Y12 inhibitors are broadly used worldwide to prevent and treat ischemic events in cardiac patients; however, understanding their ...
Lisa Gross, Dániel Aradi, Dirk Sibbing
openaire   +1 more source

P2Y12 Inhibitors: Pharmacologic Mechanism and Clinical Relevance

Cardiovascular & Hematological Agents in Medicinal Chemistry, 2013
Platelets play a critical role in the pathogenesis of atherothrombotic processes and inhibition of platelet aggregation by antiplatelet therapy is essential and really important in the acute coronary syndromes or in the setting of percutaneous coronary intervention.
Secco GG, Parisi R, Mirabella F, FATTORI, ROSSELLA, Genoni G, Agostoni P, De Luca G, Marino PN, Lupi A, Rognoni A.   +9 more
openaire   +3 more sources

New P2Y12 inhibitors

Heart, 2011
The management and prevention of arterial thrombosis has been transformed by the recognition of the role of platelets in this process and the development of effective antiplatelet drugs. The limited role of thromboxane A2 in platelet activation explains why aspirin therapy, which effectively inhibits release of thromboxane A2 by platelets, is ...
openaire   +1 more source

Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay

Thrombosis and Haemostasis, 2013
SummaryVerifyNow (VN) P2Y12 is a point-of-care assay used to assess response to P2Y12 inhibitors. Sodium citrate (citrate) is the standard anticoagulant used for this assay but requires a pre-incubation period. Hirudin is an alternative anticoagulant for platelet function studies that maintains physiological divalent cation levels.
Robert Storey, Allison Morton, Heather Judge, Rosemary Ecob, Kate Howgego, Amrita Dhutia, Sonal Mehra, Rebecca Daly, Wael Sumaya   +8 more
openaire   +1 more source

P2Y12 Is Involved in Cancer Metastasis,

Blood, 2011
Abstract Abstract 3356 The platelet ADP receptor P2Y12 plays a prominent role in amplifying platelet activation, aggregation and thrombus formation, and the P2Y12 inhibitor Clopidogrel is widely used clinically to treat coronary artery, peripheral vascular and cerebrovascular diseases.
Yanhua Wang, Yueping Sun, Ding Li, Lin Zhang, Kemin Wang, Weiran Chai, Xinping Luo, T. Kent Gartner, Junling Liu   +8 more
openaire   +1 more source

P2Y12-Independent Transient Activation and P2Y12-Dependent Prolonged Activation of Platelet Integrin αIIbβ3.

Blood, 2006
Abstract Affinity of platelet integrin αIIbβ3 for ligands is dynamically regulated and the activation of αIIbβ3 has been analyzed by binding assays using fibrinogen or ligand mimetic antibodies such as PAC1. Ligand binding assays are suitable for the condition when the number of receptors would reach a plateau phase before the end of ...
Masamichi Shiraga, Tsuyoshi Kamae, Masao Akiyama, Seiji Tadokoro, Hirokazu Kashiwagi, Kenji Oritani, Yoshiyuki Kurata, Yoshiaki Tomiyama, Yuzuru Kanakura   +8 more
openaire   +1 more source

Biology and Pharmacology of the Platelet P2Y12 Receptor

Current Pharmaceutical Design, 2006
Platelets possess two receptors for ADP, P2Y(1) and P2Y(12). ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y(1) receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation.
openaire   +2 more sources

Abstract 599: Lighting Up P2Y12 Oligomers: Insights into the Role of Oligomerization in P2Y12 Function

Arteriosclerosis, Thrombosis, and Vascular Biology, 2015
Introduction: Little is known about the role of P2Y12 oligomerization in receptor function and whether P2Y12 receptor mutations associated with human bleeding disorders may be explained by alterations in oligomerization. Objectives: 1) To determine whether P2Y12 homo- and ...
Aasma Khan, Jeffrey L Caplan, Donna Woulfe   +2 more
openaire   +1 more source

Thienopyrimidine-based P2Y12 platelet aggregation inhibitors

Bioorganic & Medicinal Chemistry Letters, 2009
Herein we describe the design and synthesis of a novel series of potent thienopyrimidine P2Y12 inhibitors and the negative impact protein binding has on the inhibition of platelet aggregation.
Steven W, Kortum, Rhonda M, Lachance, Barbara A, Schweitzer, Gopichand, Yalamanchili, Hayat, Rahman, Michael D, Ennis, Rita M, Huff, Ruth E, TenBrink   +7 more
openaire   +2 more sources

Progress in Platelet Blockers: The Target is the P2Y12 Receptor

Journal of Cardiothoracic and Vascular Anesthesia, 2013
The considerable progress in P2Y12-platelet blockers has important perioperative implications due to a family of novel agents beyond clopidogrel. Although prasugrel is more potent than clopidogrel due to more efficient hepatic metabolism, it is limited clinically by its irreversibility and bleeding risks.
Prakash A, Patel, Bernard, Lane, John G T, Augoustides   +2 more
openaire   +2 more sources